Premium
DIURNAL RHYTHM OF SERUM gM‐SEMINOPROTEIN IN PATIENTS WITH UNTREATED PROSTATE CANCER: COMPARISON OF THE ORIGINAL AND REVISED ASSAY KITS
Author(s) -
Akimoto Susumu,
Akakura Koichiro,
Ohki Takemasa,
Shimazaki Jun
Publication year - 1994
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.1994.tb00047.x
Subject(s) - medicine , coefficient of variation , prostate cancer , prostatic acid phosphatase , radioimmunoassay , prostate specific antigen , endocrinology , cancer , chromatography , chemistry
To compare levels of y‐seminoprotein (gM‐Sm) assayed by original and revised assay systems, blood was obtained every 4 h over a 32‐h period from 8 untreated prostate cancer patients. Serum levels of prostate specific antigen (PSA) were also examined. In 6 patients, the coefficient of variation (CV) of the serum levels assayed by the revised assay was significantly different from that of the intra‐assay samples. In contrast, the CV of the gM‐Sm serum levels assayed by the original assay differed significantly from that of the intra‐assay samples in only 2 patients. The fluctuations in gM‐Sm assayed by the revised assay were, at least in part, similar to those of the PSA serum levels in all patients. The mean CV of the gM‐Sm serum levels assayed by the revised assay was significantly larger than that for levels measured by the original assay. After treatment, the rate of decrease in gM‐Sm serum levels determined by the original assay differed from that in the serum levels of PSA and prostatic acid phosphatase. These results indicate that the original assay for gM‐Sm do not detect diurnal differences in serum gM‐Sm levels, even at levels below 20 ng/ml. These observations indicate that the analysis of data obtained using the original gM‐Sm kit should be interpreted with caution.